Clinical Trial Update: A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab [Phase 4]

View source ↗

Summary

This Phase 4 open-label study evaluated the immune response to COVID-19 vaccination in people with relapsing multiple sclerosis treated with ofatumumab. The tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Multiple Sclerosis (RMS) | Phase 4 | Status: TERMINATED | Results posted: 2024-06-20